Ankylosing Spondylitis Treatment Market
Ankylosing Spondylitis Treatment Market Size, Share & Trends Analysis Report, By Drug Class (NSAIDs, Biologics, Targeted Synthetic DMARDs, Conventional Synthetic DMARDs, Corticosteroids), By Treatment Line (First-Line Therapy, Second-Line Therapy, Third-Line / Refractory Treatment), By End User (Hospitals, Specialty Clinics, Homecare Settings), Forecast Period (2026–2035)
Industry Overview
Ankylosing spondylitis treatment market size is valued at $6.5 billion in 2025 and is projected to reach $11.2 billion by 2035, growing at a CAGR of 5.6% during 2026–2035. The market is primarily driven by the increasing prevalence of autoimmune diseases, advancements in biologic therapies, and improved diagnostic capabilities across healthcare systems.
According to the World Health Organization (WHO), musculoskeletal conditions impact over 1.71 billion people globally, making them one of the leading causes of disability worldwide. Ankylosing spondylitis, a chronic inflammatory disorder affecting the spine and joints, contributes significantly to this burden. Additionally, data from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights continued investment in immunology drug development, particularly biologics and targeted therapies, fueling innovation in treatment approaches.
End-use demand is concentrated across hospitals, specialty clinics, and home care settings, with biologics and targeted synthetic DMARDs gaining traction due to improved efficacy and patient outcomes. The shift toward personalized medicine and early intervention strategies is further accelerating market growth globally.
Market Dynamics
Rising Prevalence of Autoimmune Diseases Driving Market Growth
The increasing burden of autoimmune diseases is a key factor driving the ankylosing spondylitis treatment market. According to the WHO, chronic inflammatory and musculoskeletal conditions are a leading contributor to global disability, impacting workforce productivity and healthcare systems. Furthermore, the U.S. Food and Drug Administration (FDA) has reported a steady rise in approvals for biologics and targeted therapies, reflecting strong innovation in immunology treatments.
Healthcare systems globally are investing in early diagnosis and long-term disease management, increasing treatment adoption rates. Pharmaceutical companies are responding by expanding biologic pipelines, improving patient accessibility, and enhancing therapeutic outcomes. Between 2025 and 2026, companies are focusing on next-generation IL-17 inhibitors and JAK inhibitors, which offer superior disease control and patient compliance. This trend is expected to significantly boost the ankylosing spondylitis treatment market growth over the forecast period.
High Treatment Costs and Biosimilar Competition as Market Challenges
Despite strong growth prospects, the ankylosing spondylitis treatment market faces challenges related to high treatment costs and pricing pressures. Biologic therapies, which dominate the market, are expensive and often require long-term administration, limiting accessibility in developing regions.
According to Pharmaceutical Research and Manufacturers of America (PhRMA), biologics account for a substantial share of specialty drug spending, increasing the financial burden on healthcare systems. Additionally, the emergence of biosimilars is intensifying price competition, impacting revenue growth for innovator companies.
Supply chain complexities and regulatory hurdles further add to market challenges. However, companies are addressing these issues through biosimilar development, cost optimization strategies, and partnerships aimed at improving affordability and access to advanced therapies.
Market Segmentation
- Based on the drug class, the market is segmented into NSAIDs, biologics, targeted synthetic DMARDs, conventional synthetic DMARDs, and corticosteroids.
- Based on the treatment line, the market is segmented into first-line therapy, second-line therapy, and third-line / refractory treatment.
- Based on the end user, the market is segmented into hospitals, specialty clinics, and home care settings.
Biologics Segment Leads the Market
The biologics segment dominates the ankylosing spondylitis treatment market due to its superior clinical efficacy in reducing inflammation and preventing disease progression. TNF inhibitors and IL-17 inhibitors are widely prescribed, particularly in patients who do not respond to NSAIDs.
Between 2022 and 2026, companies have significantly expanded biologic portfolios. Major players have focused on lifecycle management strategies, label expansions, and global accessibility initiatives. The adoption of biologics is particularly high in developed markets such as North America and Europe, where reimbursement frameworks support advanced therapies. Continuous innovation in biologic drugs is expected to sustain their dominance in the market.
Targeted Synthetic DMARDs Segment to Record Strong Growth
The targeted synthetic DMARDs (tsDMARDs) segment is projected to register the fastest growth during the forecast period. These therapies, particularly JAK inhibitors, offer oral administration, improved patient convenience, and comparable efficacy to biologics.
Advancements in molecular targeting and precision medicine are driving the adoption of tsDMARDs. Pharmaceutical companies are investing heavily in R&D to develop next-generation therapies with improved safety profiles. Increasing preference for oral therapies among patients and physicians is further boosting demand, making tsDMARDs a key growth segment in the ankylosing spondylitis treatment market.
Regional Outlook
The global ankylosing spondylitis treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the ankylosing spondylitis treatment market due to advanced healthcare infrastructure and high adoption of biologics. According to the FDA, the U.S. continues to lead in biologic drug approvals, supporting innovation in autoimmune disease treatments. Additionally, strong reimbursement systems and high healthcare expenditure contribute to increased patient access to advanced therapies.
China to Record Strong Growth
China is expected to witness the fastest growth due to expanding healthcare infrastructure and rising disease awareness. According to the International Trade Centre (ITC), pharmaceutical trade and manufacturing activities in China have grown significantly, supporting domestic production and availability of biologics and biosimilars. Government initiatives aimed at improving healthcare access are further driving market expansion.
Competitive Landscape
The ankylosing spondylitis treatment market is highly competitive, characterized by the presence of leading pharmaceutical companies focusing on biologics and targeted therapies. Companies such as AbbVie, Amgen, Pfizer, Novartis, and Eli Lilly and Company dominate the market through strong product portfolios and continuous innovation. These players are leveraging advanced R&D capabilities, strategic partnerships, and global distribution networks to maintain their competitive edge. Increasing competition from biosimilar manufacturers is also reshaping market dynamics, leading to pricing pressure and expanded access.
Recent Developments
- In February 2026, AbbVie accelerated its post-Humira transition strategy by scaling next-generation immunology therapies such as Rinvoq, which is gaining traction in ankylosing spondylitis treatment. This shift reflects a broader market transition toward advanced targeted therapies following biosimilar-driven erosion of legacy biologics.
- In October 2024, Johnson & Johnson assumed full commercial responsibility for Remicade and Simponi in the UK. Both therapies are widely used in the treatment of Ankylosing Spondylitis, and this transition strengthens the company’s immunology portfolio while ensuring continued patient access and reinforcing its competitive position in the ankylosing spondylitis treatment market.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global ankylosing spondylitis treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Ankylosing Spondylitis Treatment Market Sales Analysis – Drug Class | Treatment Line | End User ($ Million)
- Ankylosing Spondylitis Treatment Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Ankylosing Spondylitis Treatment Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Ankylosing Spondylitis Treatment Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Ankylosing Spondylitis Treatment Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Ankylosing Spondylitis Treatment Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Ankylosing Spondylitis Treatment Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Ankylosing Spondylitis Treatment Market Revenue and Share by Manufacturers
- Ankylosing Spondylitis Treatment Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 AbbVie
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Amgen
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Pfizer
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Novartis
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Eli Lilly and Company
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Ankylosing Spondylitis Treatment Market Sales Analysis by Drug Class ($ Million)
5.1 NSAIDs
5.2 Biologics
5.3 Targeted Synthetic DMARDs (tsDMARDs)
5.4 Conventional Synthetic DMARDs (csDMARDs)
5.5 Corticosteroids
- Global Ankylosing Spondylitis Treatment Market Sales Analysis by Treatment Line ($ Million)
6.1 First-Line Therapy
6.2 Second-Line Therapy
6.3 Third-Line / Refractory Treatment
- Global Ankylosing Spondylitis Treatment Market Sales Analysis by End User ($ Million)
7.1 Hospitals
7.2 Specialty Clinics
7.3 Homecare Settings
- Global Ankylosing Spondylitis Treatment Market Sales Analysis by Geography ($ Million)
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Latin America
8.5 Middle East & Africa
- Regional Analysis
9.1 North American Ankylosing Spondylitis Treatment Market Sales Analysis – Drug Class | Treatment Line | End User Country ($ Million)
9.1.1 United States
9.1.2 Canada
9.2 European Ankylosing Spondylitis Treatment Market Sales Analysis – Drug Class | Treatment Line | End User Country ($ Million)
9.2.1 UK
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 France
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Asia-Pacific Ankylosing Spondylitis Treatment Market Sales Analysis – Drug Class | Treatment Line | End User Country ($ Million)
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 ASEAN Countries
9.3.7 Rest of Asia-Pacific
9.4 Rest of the World Ankylosing Spondylitis Treatment Market Sales Analysis – Drug Class | Treatment Line | End User Country ($ Million)
9.4.1 Latin America
9.4.2 Middle East and Africa
- Company Profiles
10.1 AstraZeneca
10.1.1 Quick Facts
10.1.2 Company Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.2 Biocon Biologics
10.2.1 Quick Facts
10.2.2 Company Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.3 Boehringer Ingelheim
10.3.1 Quick Facts
10.3.2 Company Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.4 Bristol Myers Squibb
10.4.1 Quick Facts
10.4.2 Company Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.5 Celltrion
10.5.1 Quick Facts
10.5.2 Company Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.6 Dr. Reddy’s Laboratories
10.6.1 Quick Facts
10.6.2 Company Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.7 GSK
10.7.1 Quick Facts
10.7.2 Company Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.8 Hikma Pharmaceuticals
10.8.1 Quick Facts
10.8.2 Company Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.9 Johnson & Johnson
10.9.1 Quick Facts
10.9.2 Company Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.10 Johnson & Johnson
10.10.1 Quick Facts
10.10.2 Company Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.11 Lupin Limited
10.11.1 Quick Facts
10.11.2 Company Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.12 Merck & Co.
10.12.1 Quick Facts
10.12.2 Company Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.13 Samsung Bioepis
10.13.1 Quick Facts
10.13.2 Company Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.14 Sandoz
10.14.1 Quick Facts
10.14.2 Company Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.15 Sanofi
10.15.1 Quick Facts
10.15.2 Company Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.16 Sun Pharma
10.16.1 Quick Facts
10.16.2 Company Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.17 Teva Pharmaceutical
10.17.1 Quick Facts
10.17.2 Company Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies
10.18 Torrent Pharmaceuticals
10.18.1 Quick Facts
10.18.2 Company Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies
10.19 UCB
10.19.1 Quick Facts
10.19.2 Company Overview
10.19.3 Product Portfolio
10.19.4 Business Strategies
10.20 Zydus Lifesciences
10.20.1 Quick Facts
10.20.2 Company Overview
10.20.3 Product Portfolio
10.20.4 Business Strategies
1. Global Ankylosing Spondylitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
2. Global NSAIDs Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Biologics Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Targeted Synthetic DMARDs (tsDMARDs) Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Conventional Synthetic DMARDs (csDMARDs) Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Corticosteroids Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Ankylosing Spondylitis Treatment Market Research and Analysis by Treatment Line, 2025–2035 ($ Million)
8. Global First-Line Therapy Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Second-Line Therapy Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Third-Line / Refractory Treatment Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Ankylosing Spondylitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
12. Global Ankylosing Spondylitis Treatment for Hospitals Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Ankylosing Spondylitis Treatment for Specialty Clinics Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Ankylosing Spondylitis Treatment for Homecare Settings Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
16. North America Ankylosing Spondylitis Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
17. North America Ankylosing Spondylitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
18. North America Ankylosing Spondylitis Treatment Market Research and Analysis by Treatment Line, 2025–2035 ($ Million)
19. North America Ankylosing Spondylitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
20. Europe Ankylosing Spondylitis Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
21. Europe Ankylosing Spondylitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
22. Europe Ankylosing Spondylitis Treatment Market Research and Analysis by Treatment Line, 2025–2035 ($ Million)
23. Europe Ankylosing Spondylitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
24. Asia-Pacific Ankylosing Spondylitis Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
25. Asia-Pacific Ankylosing Spondylitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
26. Asia-Pacific Ankylosing Spondylitis Treatment Market Research and Analysis by Treatment Line, 2025–2035 ($ Million)
27. Asia-Pacific Ankylosing Spondylitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
28. Rest of the World Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
29. Rest of the World Ankylosing Spondylitis Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
30. Rest of the World Ankylosing Spondylitis Treatment Market Research and Analysis by Treatment Line, 2025–2035 ($ Million)
31. Rest of the World Ankylosing Spondylitis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
1. Global Ankylosing Spondylitis Treatment Market Share by Drug Class, 2025 Vs 2035 (%)
2. Global NSAIDs Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
3. Global Biologics Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
4. Global Targeted Synthetic DMARDs (tsDMARDs) Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
5. Global Conventional Synthetic DMARDs (csDMARDs) Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
6. Global Corticosteroids Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
7. Global Ankylosing Spondylitis Treatment Market Share by Treatment Line, 2025 Vs 2035 (%)
8. Global First-Line Therapy Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
9. Global Second-Line Therapy Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
10. Global Third-Line / Refractory Treatment Ankylosing Spondylitis Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)
11. Global Ankylosing Spondylitis Treatment Market Share by End User, 2025 Vs 2035 (%)
12. Global Ankylosing Spondylitis Treatment for Hospitals Market Research and Analysis by Region, 2025 Vs 2035 (%)
13. Global Ankylosing Spondylitis Treatment for Specialty Clinics Market Research and Analysis by Region, 2025 Vs 2035 (%)
14. Global Ankylosing Spondylitis Treatment for Homecare Settings Market Research and Analysis by Region, 2025 Vs 2035 (%)
15. Global Ankylosing Spondylitis Treatment Market Share by Region, 2025 Vs 2035 (%)
16. U.S. Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
17. Canada Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
18. UK Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
19. France Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
20. Germany Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
21. Italy Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
22. Spain Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
23. Russia Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
24. India Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
25. China Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
26. Japan Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
27. South Korea Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
28. Australia & New Zealand Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
29. ASEAN Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
30. Rest of Asia-Pacific Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
31. Latin America Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
32. Middle East & Africa Ankylosing Spondylitis Treatment Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
